Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Gascon R, Tsou CL, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Morris MK, Wadford D, Hanson C, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna JA, Ott M. Suryawanshi RK, et al. Among authors: nguyen j. Nature. 2022 Jul;607(7918):351-355. doi: 10.1038/s41586-022-04865-0. Epub 2022 May 18. Nature. 2022. PMID: 35584773 Free PMC article.
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park Y, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt ND, Kang TH, Wu X, Rogers TF, Manuel ER, Shostak Y, Diamond DJ, Wussow F. Chiuppesi F, et al. Among authors: nguyen j, nguyen vh. Nat Commun. 2020 Nov 30;11(1):6121. doi: 10.1038/s41467-020-19819-1. Nat Commun. 2020. PMID: 33257686 Free PMC article.
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, Sreekumar B, Khalid MM, Ciling A, Chen PY, Kumar GR, Gliwa AS, Nguyen J, Sotomayor-Gonzalez A, Zhang Y, Frias E, Prostko J, Hackett J Jr, Andino R, Wadford DA, Hanson C, Doudna J, Ott M, Chiu CY. Servellita V, et al. Among authors: nguyen j. Cell. 2022 Apr 28;185(9):1539-1548.e5. doi: 10.1016/j.cell.2022.03.019. Epub 2022 Mar 18. Cell. 2022. PMID: 35429436 Free PMC article.
Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections.
Brazer N, Morris MK, Servellita V, Anglin K, Saldhi P, Garcia-Knight M, Bethancourt S, Sotomayor-Gonzalez A, Wang B, Foresythe A, Nguyen J, Gliwa AS, Pineda-Ramirez J, Sanchez RD, Zhang Y, Ott M, Wadford DA, Andino R, Kelly JD, Hanson C, Chiu CY. Brazer N, et al. Among authors: nguyen j. J Infect Dis. 2022 Nov 11;226(10):1688-1698. doi: 10.1093/infdis/jiac384. J Infect Dis. 2022. PMID: 36134603 Free PMC article.
Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Suryawanshi RK, Taha TY, McCavitt-Malvido M, Silva I, Khalid MM, Syed AM, Chen IP, Saldhi P, Sreekumar B, Montano M, Foresythe K, Tabata T, Kumar GR, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Kojima N, Arellanor T, Bussanich A, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Wang Y, Ghazarian S, Davis G, Rodriguez D, Doudna J, Spraggon L, Chiu CY, Ott M. Suryawanshi RK, et al. Among authors: nguyen j. Emerg Microbes Infect. 2023 Dec;12(2):2270071. doi: 10.1080/22221751.2023.2270071. Epub 2023 Oct 31. Emerg Microbes Infect. 2023. PMID: 37869789 Free PMC article.
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.
Chiuppesi F, Zaia JA, Frankel PH, Stan R, Drake J, Williams B, Acosta AM, Francis K, Taplitz RA, Dickter JK, Dadwal S, Puing AG, Nanayakkara DD, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen VH, Francisco SO, Grifoni A, Wong A, Sette A, Wussow F, Diamond DJ. Chiuppesi F, et al. Among authors: nguyen j, nguyen vh. Lancet Microbe. 2022 Apr;3(4):e252-e264. doi: 10.1016/S2666-5247(22)00027-1. Epub 2022 Mar 9. Lancet Microbe. 2022. PMID: 35287430 Free PMC article. Clinical Trial.
Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.
Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park S, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt ND, Kang TH, Wu X, Rogers T, Manuel ER, Shostak Y, Diamond DJ, Wussow F. Chiuppesi F, et al. Among authors: nguyen j, nguyen vh. bioRxiv [Preprint]. 2020 Jul 2:2020.07.01.183236. doi: 10.1101/2020.07.01.183236. bioRxiv. 2020. PMID: 32637957 Free PMC article. Updated. Preprint.
Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice.
Chiuppesi F, Wussow F, Scharf L, Contreras H, Gao H, Meng Z, Nguyen J, Barry PA, Bjorkman PJ, Diamond DJ. Chiuppesi F, et al. Among authors: nguyen j. PLoS One. 2017 Aug 16;12(8):e0183377. doi: 10.1371/journal.pone.0183377. eCollection 2017. PLoS One. 2017. PMID: 28813507 Free PMC article.
Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
Chiuppesi F, Salazar MD, Contreras H, Nguyen V, Martinez J, Park S, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt N, Kang T, Wu X, Rogers T, Manuel E, Shostak Y, Diamond D, Wussow F. Chiuppesi F, et al. Among authors: nguyen j, nguyen v. Res Sq [Preprint]. 2020 Jul 17:rs.3.rs-40198. doi: 10.21203/rs.3.rs-40198/v1. Res Sq. 2020. PMID: 32702732 Free PMC article. Updated. Preprint.
3,351 results